natgillin/translations-raw huggingface dataset:
I BzR-CAP-gruppen fik 22,5 % af patienterne trombocyttransfusioner sammenlignet med 2,9 % af patienterne i R-CHOP-gruppen. 
In the BzR-CAP group, 22.5% of patients received platelet transfusions compared to 2.9% of patients in the R-CHOP group.
Det Europæiske Lægemiddelagentur har dispenseret fra kravet om at fremlægge resultaterne af studier med bortezomib i alle undergrupper af den pædiatriske population ved myelomatose og ved mantlecelle-lymfom (se pkt. 
The European Medicines Agency has waived the obligation to submit the results of studies with bortezomib in all subsets of the paediatric population in multiple myeloma and in mantle cell lymphoma (see section 4.2 for information on paediatric use).
Den mediane varighed af komplet respons var 42,1 måneder i BzR-CAP-gruppen sammenlignet med 18 måneder i R-CHOP-gruppen. 
The median duration of complete response was 42.1 months in the BzR-CAP group compared with 18 months in the R-CHOP group.
Behandlingen med bortezomib forbindes almindeligvis med ortostatisk/postural hypotension. 
Bortezomib treatment is commonly associated with orthostatic/postural hypotension.
Du kan ligeledes få Bortezomib Accord sammen med lægemidlerne pegyleret liposomal doxorubicin eller dexamethason. 
You may also be given Bortezomib Accord together with the medicines pegylated liposomal doxorubicin or dexamethasone.
Der blev observeret en statistisk signifikant fordel (p < 0,001) for BzR-CAP-gruppen i forhold til R-CHOP-gruppen for TTP (median 30,5 kontra 16,1 måneder), TNT (median 44,5 kontra 24,8 måneder) og TFI (median 40,6 kontra 20,5 måneder). 
A statistically significant benefit (p < 0.001) in favour of the BzR-CAP treatment group over the R-CHOP group was observed for TTP (median 30.5 versus 16.1 months), TNT (median 44.5 versus 24.8 months) and TFI (median 40.6 versus 20.5 months).
Kombinationsbehandling med rituximab, cyclophosphamid, doxorubicin og prednison (BzR-CAP) 
Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (BzR-CAP)
De to behandlingsgrupper var sammenlignelige, hvad angår den samlede forekomst af alle grader af blødningshændelser (6,3 % i BzR-CAP-gruppen og 5,0 % i R-CHOP-gruppen) såvel som blødningshændelser af grad 3 og højere (BzR-CAP: 4 patienter [1,7 %]; R-CHOP: 3 patienter [1,2 %]). 
The two treatment groups were similar with regard to the overall incidence of all-grade bleeding events (6.3% in the BzR-CAPgroup and 5.0% in the R-CHOP group) as well as Grade 3 and higher bleeding events (BzR-CAP: 4 patients [1.7%]; R-CHOP: 3 patients [1.2%]).
Seks bortezomib-cyklusser anbefales, men patienter med et respons, som først dokumenteres ved cyklus 6, kan gives yderligere to bortezomib-cyklusser. 
Six bortezomib cycles are recommended, although for patients with a response first documented at cycle 6, two additional bortezomib cycles may be given.
Hætteglas inden anbrud 2 år (for Bortezomib Accord 1 mg) 3 år (for Bortezomib Accord 3,5 mg) 
2 years (for Bortezomib Accord 1 mg) 3 years (for Bortezomib Accord 3.5 mg)
Tabel 8: Bivirkninger hos patienter med mantle-celle-lymfom, som blev behandlet med BzR-CAP i et klinisk studie 
Table 8 Adverse reactions in patients with Mantle cell lymphoma treated with BzR-CAP in a clinical trial
I tilfælde af bortezomib-relateret neuropatisk smerte og/eller perifer neuropati indstilles og/eller modificeres Bortezomib Accord-behandlingen som beskrevet i tabel 1. 
For bortezomib-related neuropathic pain and/or peripheral neuropathy, hold and/or modify Bortezomib Accord as outlined in Table 1.
Bortezomib-kombinationsbehandling med pegyleret liposomal doxorubicin (studie DOXILMMY-3001) 
Bortezomib combination treatment with pegylated liposomal doxorubicin (study DOXIL-MMY-3001)
Analysen påviste forbedret ORR (CR+PR) (odds-ratio 3,769; 95 % CI 2,045-6,947; p < 0,001), PFS (hazard ratio 0,511; 95 % CI 0,309--0,845; p=0,008), TTP (hazard ratio 0,385; 95 % CI 0,212--0,698; p = 0,001) for bortezomib sammen med dexamethason over bortezomib som monoterapi. 
The analysis demonstrated improved ORR (CR+PR) (odds ratio 3.769; 95% CI 2.045-6.947; p < 0.001), PFS (hazard ratio 0.511; 95% CI 0.309-0.845; p=0.008), TTP (hazard ratio 0.385; 95% CI 0.212-0.698; p=0.001) for bortezomib in combination with dexamethasone over bortezomib monotherapy.
Særligt skal du fortælle lægen, hvis du bruger medicin, som indeholder følgende aktive stoffer: - ketoconazol, som bruges til behandling af svampeinfektioner - ritonavir, bruges til behandling af Hiv-infektion - rifampicin, et antibiotikum, som bruges til at behandle bakterie-infektioner - carbamazepin, phenytoin eller phenobarbital til behandling af epilepsi - perikon (Hypericum perforatum), naturmedicin som bruges mod depression eller andre lidelser - tabletter til behandling af sukkersyge (diabetes) 
In particular, tell your doctor if you are using medicines containing any of the following active substances: - ketoconazole, used to treat fungal infections - ritonavir, used to treat HIV infection - rifampicin, an antibiotic used to treat bacterial infections - carbamazepine, phenytoin or phenobarbital used to treat epilepsy - St. John's Wort (Hypericum perforatum), used for depression or other conditions - oral antidiabetics
Kun til subkutan eller intravenøs anvendelse. 
Subcutaneous or Intravenous use.
Da dialyse kan reducere koncentrationen af bortezomib, bør Bortezomib Accord gives efter dialyse (se pkt. 
Since dialysis may reduce bortezomib concentrations, Bortezomib Accord should be administered after the dialysis procedure (see section 5.2).
Demografiske og baseline-sygdomskarakteristika var generelt afbalanceret mellem de to behandlingsarme: Den mediane patientalder var 66 år, 74 % var mænd, 66 % var kaukasere og 32 % asiater, 69 % af patienterne havde et positivt knoglemarvsaspirat og/eller en positiv knoglemarvsbiopsi for MCL, 54 % af patienterne havde en IPI-score (International Prognostic Index) på ≥ 3, og 76 % var i sygdomsstadie IV. Behandlingens varighed (median=17 uger) og varigheden af opfølgningen (median=40 måneder) var sammenlignelige i de to behandlingsarme. 
The demographic and baseline disease characteristics were generally well balanced between the two treatment arms: median patient age was 66 years, 74% were male, 66% were Caucasian and 32% Asian, 69% of patients had a positive bone marrow aspirate and/or a positive bone marrow biopsy for MCL, 54% of patients had an International Prognostic Index (IPI) score of ≥ 3, and 76% had Stage IV
Tabel 7: Bivirkninger hos patienter med myelomatose behandlet med bortezomib i kliniske studier samt alle bivirkninger efter markedsføring, uanset indikation 
Table 7:Adverse reactions in patients with Multiple Myeloma treated with Bortezomib in clinical trials, and all post-marketing adverse reactions regardless of indication
Nedsat appetit 
• Increased appetite
Almindelig Leukopeni*, lymfopeni* 
Leukopenia*, Lymphopenia*
Hyperbilirubinæmi*, abnorme proteinanalyser*, vægtstigning, abnorm blodprøve*, forhøjet C-reaktivt protein 
Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*,C-reactive protein increased
Bortezomib Accord gives intravenøst eller subkutant på dag 1, 4, 8 og 11, fulgt af en ‘hvileperiode' uden behandling. 
Bortezomib Accord is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a ‘rest period' without treatment.
Responsrate efter 8 cyklusser n (%) 
Response Rate at 8 cycles n (%)
• at Bortezomib Accord 3,5 mg kan administreres enten intravenøst eller subkutant, mens Bortezomib Accord 1 mg kun må administreres intravenøst 
• Bortezomib Accord 3.5 mg can be administered both intravenously and subcutaneously, while Bortezomib Accord 1 mg can be administered only intravenously
Den mediane OS var 90,7 måneder for BzR-CAP -gruppen sammenlignet med 55,7 måneder for R-CHOP-gruppen (HR = 0,66; p = 0,001). 
Median OS was 90.7 months for the BzR-CAP group compared with 55.7 months for the R-CHOP group (HR=0.66; p=0.001).
Der er ikke data, der tyder på, at dosisjustering er nødvendig hos patienter med myelomatose eller mantle-celle-lymfom, der er ældre end 65 år. 
There is no evidence to suggest that dose adjustments are necessary in patients over 65 years of age with multiple myeloma or with mental cell lymphona.
Hændelser n (%) Mediana (95 % CI) 
Events n (%) Mediana (95% CI)
• rådgivning om intravenøs og subkutan administration, herunder at der bør skiftes mellem injektionssteder ved subkutan anvendelse 
• advice on method of administration for both intravenous and subcutaneous use, including the need to rotate injection sites for subcutaneous use
Tabel 9: Forekomst af perifer neuropati under induktionsbehandling efter toksicitet og behandlingsseponering på grund af perifer neuropati 
Table 9: Incidence of peripheral neuropathy during induction treatment by toxicity and treatment discontinuation due to peripheral neuropathy
Bortezomib Accord kan forårsage træthed, svimmelhed, besvimelse og uklart/sløret syn. 
Bortezomib Accord might cause tiredness, dizziness, fainting, or blurred vision.
54 uger) og blev seponeret før tid ved sygdomsprogression eller uacceptabel toksicitet. 
Treatment was administered for a maximum of 9 cycles (approximately 54 weeks) and was discontinued early for disease progression or unacceptable toxicity.
Melphalan og prednison bør begge gives oralt på dag 1, 2, 3 og 4 i den første uge af hver behandlingscyklus med Bortezomib Accord. 
Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each Bortezomib Accord treatment cycle.
som var refraktære over for den seneste behandling, og de, der ikke var refraktære, var den samlede overlevelse signifikant længere, og responsraten var signifikant højere i bortezomib-gruppen. 
Both in patients who were refractory to their last prior therapy and those who were not refractory, overall survival was significantly longer and response rate was significantly higher on the bortezomib arm.
Tabel 15: Oversigt over effektanalyser til sammenligning af subkutan og intravenøs administration af bortezomib bortezomib intravenøs gruppe bortezomib subkutan gruppe 
Table 15: Summary of efficacy analyses comparing subcutaneous and intravenous administrations of bortezomib bortezomib intravenous arm bortezomib subcutaneous arm
I fase III-studiet med hidtil ubehandlede myelomatosepatienter var den samlede forekomst af herpes zoster-reaktivering større hos patienter behandlet med bortezomib+melphalan+prednison sammenlignet med melphalan+prednison (14 % versus 4 %). 
In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with bortezomib+melphalan+prednisone compared with melphalan+prednisone (14% versus 4% respectively).
Responsrate efter 4 cyklusser n (%) 
Response Rate at 4 cycles n (%)
Absorption Efter intravenøs bolusindgift af en dosis på 1,0 mg/m2 og 1,3 mg/m2 til 11 patienter med myelomatose og kreatininclearance-værdier på mere end 50 ml/min., var de gennemsnitlige maksimale plasmakoncentrationer af bortezomib efter første dosis henholdsvis 57 og 112 ng/ml. 
Absorption Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
In vitro-studier viser, at bortezomib er en svag hæmmer af cytochrom P450 CYP-isozymer 1A2, 2C9, 2C19, 2D6 og 3A4. 
In vitro studies indicate that bortezomib is a weak inhibitor of the cytochrome P450 (CYP) isozymes 1A2, 2C9, 2C19, 2D6 and 3A4.
• for at minde patienter, der modtager Bortezomib Accord sammen med thalidomid, om, at de skal overholde det svangerskabsforebyggende program for thalidomid, og med reference til produktresuméet for thalidomid for yderligere oplysninger. 
• to remind that patients receiving Bortezomib Accord in combination with thalidomide should adhere to the pregnancy prevention programme of thalidomide, with reference to the SmPC of thalidomide for additional information.
• Trombocyttal skal være ≥ 70 x 109/l, og absolut neutrofiltal skal være ≥ 1,0 x 109/l 
• Platelet counts should be ≥ 70 x 109/l and the absolute neutrophils count should be ≥ 1.0 x 109/l
• et redskab til beregning af dosis, hvor den ordinerende læge kan indlæse patientens højde og vægt for ud fra disse at beregne arealet af legemsoverfladen og derved fastsætte en passende dosering af Bortezomib Accord. 
• a dose-calculation tool that enables prescribers to input a patient's height and weight in order to calculate the body surface area (BSA) and thereby to determine the appropriate Bortezomib Accord dose.
198 (82 %) og 208 (87 %) patienter i henholdsvis VDDx og BzDx-gruppen fik autolog stamcelletransplantation. 
Autologous stem cell transplants were received by 198 (82%) patients and 208 (87%) patients in the VDDx and BzDx groups respectively; the majority of patients underwent one single transplant procedure.
Tabel 1: Anbefalede* dosisændringer ved Bortezomib Accord-relateret neuropati 
Table 1: Recommended* posology modifications for Bortezomib Accord -related neuropathy
I et studie, hvor bortezomib-behandling blev gentaget hos 130 patienter med recidiverende myelomatose, som tidligere havde opnået mindst partielt respons med et regime, der omfattede bortezomib, var de hyppigste bivirkninger af alle grader, der indtraf hos mindst 25 % af patienterne, trombocytopeni (55 %), neuropati (40 %), anæmi (37 %), diaré (35 %) og obstipation (28 %). 
In a study in which bortezomib retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a bortezomib-containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%), neuropathy (40%), anaemia (37%), diarrhoea (35%), and constipation (28%).
- Godartede cyster - En alvorlig, reversibel tilstand i hjernen, der omfatter krampeanfald, højt blodtryk, hovedpine, 
• A severe reversible brain condition which includes seizures, high blood pressure, headaches,
Bortezomibs farmakokinetik blev karakteriseret efter intravenøs bolus-administration af 1,3 mg/m2 to gange om ugen hos 104 pædiatriske patienter (2-16 år) med akut lymfoblastær leukæmi (ALL) eller akut myeloid leukæmi (AML). 
The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 paediatric patients (2-16 years old) with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML).
Dosisjusteringer i behandlingsforløbet og ved genoptagelse af behandling ved monoterapi 
Dose adjustments during treatment and re-initiation of treatment for monotherapy
Bortezomib Accord skal rekonstitueres af sundhedspersonale (se pkt. 
Bortezomib Accord must be reconstituted by a healthcare professional (see section 6.6).
Bortezomib Accord er kun til engangsbrug. 
Bortezomib Accord is for single use only.
Reducer Bortezomib Accord til 1,0 mg/m2 
Reduce Bortezomib Accord to 1.0 mg/m2
Bortezomib Accord-behandlingen skal indstilles, indtil symptomerne på toksicitet er bedret til grad 2 eller bedre. 
Bortezomib Accord therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better.
Fra et mikrobiologisk synspunkt bør den rekonstituerede opløsning anvendes umiddelbart efter tilberedning, med mindre metoden til åbning/rekonstitution/fortynding udelukker risikoen for mikrobiel forurening. 
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the reconstituted solution should be used immediately after preparation.
Kun IV. 
IV only
Ved efterfølgende doser lå de gennemsnitlige maksimale observerede plasmakoncentrationer på 67-106 ng/ml for en dosis på 1,0 mg/m2 og på 89-120 ng/ml for en dosis på 1,3 mg/m2. 
In subsequent doses, mean maximum observed plasma concentrations ranged from 67 to 106 ng/ml for the 1.0 mg/m2 dose and 89 to 120 ng/ml for the 1.3 mg/m2 dose.
Forekomsten af herpes zoster blandt patienter i Bz+M+P-behandlingsgruppen var 17 % hos patienter, der ikke havde fået antiviral profylakse, sammenlignet med 3 % hos patienter, der havde fået antiviral profylakse. 
The incidence of herpes zoster among patients in the Bz+M+P treatment group was 17% for patients not administered antiviral prophylaxis compared to 3% for patients administered antiviral prophylaxis.
Hvis du ikke er blevet behandlet for myelomatose tidligere, og du ikke er egnet til at få transplantation med blodstamceller, vil du få Bortezomib Accord samtidig med to andre lægemidler; melphalan og prednison. 
If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell transplantation you will receive Bortezomib Accord together with two other medicines; melphalan and prednisone.
Kombinationsbehandling med melphalan og prednison 
Combination therapy with melphalan and prednisone
• at Bortezomib Accord 1 mg kun er til intravenøs anvendelse 
• that Bortezomib Accord 1 mg is only for intravenous use
Hazard ratio-estimat er baseret på en Cox-model stratificeret efter IPI-risiko og sygdomsstadie. 
b Hazard ratio estimate is based on a Cox's model stratified by IPI risk and stage of disease.
Patienter ≥ 75 år tolererede begge regimer dårligere, både BzR-CAP og R-CHOP (se pkt. 
In patients aged ≥ 75 years, both regimens, BzR-CAP as well as R-CHOP, were less tolerated (see section 4.8).
Median for investigatorbedømt PFS var 30,7 måneder i BzR-CAP-gruppen og 16,1 måneder i R-CHOP-gruppen (Hazard ratio [HR]=0,51; p < 0,001). 
Median PFS by investigator assessment was 30.7 months in the BzR-CAP group and 16.1 months in the R-CHOP group (Hazard Ratio [HR]=0.51; p < 0.001).
Der blev på grund af mangel på en direkte sammenligning af bortezomib og bortezomib i kombination med dexamethason hos patienter med progressiv myelomatose, gennemført en statistisk "matchet par"analyse for at sammenligne resultaterne fra den ikke-randomiserede arm med bortezomib i kombination med dexamethason (åbent fase II-studie MMY-2045) med resultaterne fra bortezomibmonoterapiarmene fra forskellige randomiserede fase III-studier (M34101-039 [APEX] og DOXIL MMY-3001) med samme indikation. 
In the absence of any direct comparison between bortezomib and bortezomib in combination with dexamethasone in patients with progressive multiple myeloma, a statistical matched-pair analysis was conducted to compare results from the non randomised arm of bortezomib in combination with dexamethasone (Phase II open-label study MMY-2045), with results obtained in the bortezomib monotherapy arms from different Phase III randomised studies (M34101-039 [APEX] and DOXIL MMY-3001) in the same indication.
Varigheden af det samlede respons var 21,4 måneder længere i BzR-CAP-gruppen (median 36,5 måneder kontra 15,1 måneder i R-CHOP-gruppen). 
The duration of overall response was 21.4 months longer in the BzR-CAP group (median 36.5 months versus 15.1 months in the R-CHOP group).
Kombinationsbehandling med pegyleret liposomal doxorubicin 
Combination therapy with pegylated liposomal doxorubicin
Når toksiciteten er forsvundet, gives Bortezomib Accord igen, dosis reduceres til 0,7 mg/m2 en gang om ugen. 
When toxicity resolves re-initiate Bortezomib Accord treatment and reduce dose to 0.7 mg/m2 once per week.
- Leverbetændelse - Alvorlig allergisk reaktion (anafylaktisk reaktion). 
• Hypersensitivity (allergic reaction)
• Hvis trombocyttallet er ≤ 30 × 109/l eller ANC-værdien ≤ 0,75 x 109/l på en Bortezomib Accord-dosisdag (bortset fra dag 1) 
• If platelet counts ≤ 30 x 109/l or ANC ≤ 0.75 x 109/l on a Bortezomib Accord dosing day (other than day 1)
Mantel-Haenszel-estimat af den fælles oddsratio for stratificerede tabeller er benyttet, med IPI-risiko og sygdomsstadie som stratifkationsfaktorer. 
e Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
• at kravene til rekonstitution er forskellige ved intravenøs og subkutan anvendelse 
• different reconstitution requirements for intravenous or subcutaneous use
Forekomsten af herpes zoster blandt patienter i BzR-CAP-armen var 10,7 % hos patienter, der ikke havde fået antiviral profylakse, sammenlignet med 3,6 % hos patienter, der havde fået antiviral profylakse (se pkt. 
The incidence of herpes zoster among patients in the BzR-CAP arm was 10.7% for patients not administered antiviral prophylaxis compared to 3.6% for patients administered antiviral prophylaxis (see section 4.4).
Bz= Bortezomib Accord; Dx=dexamethason; T=thalidomid a Thalidomid-dosis øges kun til 100 mg fra uge 3 i cyklus 1, hvis 50 mg tåles, og til 200 mg fra og med cyklus 2, hvis 100 mg tåles. 
Bz= Bortezomib Accord; Dx=dexamethasone; T=thalidomide a Thalidomide dose is increased to 100 mg from week 3 of Cycle 1 only if 50 mg is tolerated and to 200 mg from cycle 2
OR; 95 % CI; P værdia 
OR; 95% CI; P valuea
• rådgivning om reduktion af risikoen for at forveksle sprøjter til intravenøs og subkutan anvendelse 
• advice on how to reduce the risk of mix-up of intravenous and subcutaneous reconstituted syringes
Overvej dosisøgning til 1,0 mg/m2 eller yderligere dosisreduktion til 0,5 mg/m2 
Consider dose escalation to 1.0 mg/m2 or further dose reduction to 0.5 mg/m2
Pegyleret liposomal doxorubicin administreres i en dosis på 30 mg/ m2 på dag 4 af Bortezomib Accord behandlingscyklussen som en 1-times intravenøs infusion, der administreres efter Bortezomib Accordinjektionen. 
Pegylated liposomal doxorubicin is administered at 30 mg/m2 on day 4 of the Bortezomib Accord treatment cycle as a 1 hour intravenous infusion administered after the Bortezomib Accord injection.
Neutrofiltal var lavest på dag 11 i hver cyklus af bortezomib-behandlingen og var typisk vendt tilbage til baseline-niveau ved næste cyklus. 
Neutrophils were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle.
Dosisjustering af kombinationsbehandling for patienter med progressiv myelomatose 
Dose adjustments for combination therapy for patients with progressive multiple myeloma
Bortezomib Accord må ikke indgives via andre administrationsveje. 
Bortezomib Accord should not be given by other routes.
Tabel 2: Anbefalet dosering for Bortezomib Accord i kombination med melphalan og prednison 
Table 2: Recommended posology for Bortezomib Accord in combination with melphalan and prednisone
I fase III-studiet havde patienter, der fik bortezomib subkutant sammenlignet med som intravenøs administration en 13 % lavere samlet forekomst af behandlingsrelaterede bivirkninger i form af toksicitet af grad 3 eller derover, og en 5 % lavere forekomst af seponering af behandling med bortezomib. 
In the Phase III study patients who received bortezomib subcutaneously compared to intravenous administration had 13% lower overall incidence of treatment emergent adverse reactions that were Grade 3 or higher in toxicity, and a 5% lower incidence of discontinuation of bortezomib.
Hændelser (dødsfald) n (%) Mediana 
Events (deaths) n (%) Mediana
Følgende lægemidler gives som intravenøse infusioner på dag 1 i hver 21-ugers behandlingscyklus med Bortezomib Accord: 
The following medicinal products are given on day 1 of each Bortezomib Accord 21-day treatment cycle as intravenous infusions:
Både BzR-CAP og R-CHOP var mindre veltolereret hos patienter ≥ 75 år, og hyppigheden af alvorlige bivirkninger var i BzR-CAP-gruppen 68 % sammenlignet med 42 % i R-CHOP-gruppen. 
Although in patients aged ≥ 75 years, both BzR-CAP and R-CHOP were less tolerated, the serious adverse event rate in the BzR-CAP groups was 68%, compared to 42% in the RCHOP group.
Den gennemsnitlige TTP var 6,5 måned for patienter i monoterapi med bortezomib sammenlignet med 9,3 måneder for patienter i kombinationsbehandling med bortezomib plus pegyleret liposomal doxorubicin. 
The median TTP was 6.5 months for the bortezomib monotherapy patients compared with 9.3 months for the bortezomib plus pegylated liposomal doxorubicin combination therapy patients.